Odalasvir

Odalasvir is an investigational drug that is an NS5A inhibitor, meaning it blocks a protein in the hepatitis C virus (HCV) that is crucial for viral replication. It was developed by Achillion Pharmaceuticals for the treatment of hepatitis C, a liver infection caused by the virus. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Dimethyl ((2S, 2’S)-((2S, 2’S, 3aS, 3a’S, 7aS, 7a’S)-(1, 4(1, 4)-dibenzenacyclohexaphane-12, 43-diylbis(1H-benzo[d]imidazole-6, 2-diyl))bis(octahydro-1H-indole-2, 1-diyl))bis(3-methyl-1-oxobutane-1, 2-diyl))dicarbamate, Carbamic acid, N, N’-(tricyclo(8.2.2.24, 7)hexadeca-4, 6, 10, 12, 13, 15-hexaene-5, 11-diylbis(1H-benzimidazole-6, 2-diyl((2S, 3aS, 7aS)-octahydro-1H-indole-2, 1-diyl)((1S)-1-(1-methylethyl)-2-oxo-2, 1-ethanediyl)))bis-, C and C’-dimethyl ester. Its PubChem CID is 71474517.

CAS No 1415119-52-6
Molecular Formula C60H72N8O6
Molecular Weight 1001.3 g/mol
Synonyms methyl N-[(2S)-1-[(2S,3aS,7aS)-2-[6-[11-[2-[(2S,3aS,7aS)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindol-2-yl]-3H-benzimidazol-5-yl]-5-tricyclo[8.2.2.24,7]hexadeca-1(12),4,6,10,13,15-hexaenyl]-1H-benzimidazol-2-yl]-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

Frequently Asked Questions